We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

133 hedge funds and large institutions have $347M invested in Arcutis Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 25

4.81% more ownership

Funds ownership: 108.94% → 113.75% (+4.8%)

1% more call options, than puts

Call options by funds: $562K | Put options by funds: $557K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 40

1% less funds holding

Funds holding: 134 → 133 (-1)

3% less capital invested

Capital invested by funds: $357M → $347M (-$9.94M)

Holders
133
Holders Change
-1
Holders Change %
-0.75%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
40
Increased
50
Reduced
25
Closed
40
Calls
$562K
Puts
$557K
Net Calls
+$5K
Net Calls Change
+$3.08M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$32.5M
2
SCM
Suvretta Capital Management
New York
+$19.9M
3
Jennison Associates
Jennison Associates
New York
+$12.6M
4
Franklin Resources
Franklin Resources
California
+$9.14M
5
PCH
Polar Capital Holdings
United Kingdom
+$8.64M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$19.1M
2
O
OrbiMed
New York
-$10.2M
3
State Street
State Street
Massachusetts
-$7.71M
4
Holocene Advisors
Holocene Advisors
New York
-$6.4M
5
Marshall Wace
Marshall Wace
United Kingdom
-$6.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$2.64M +$1.24M +454,640 +125%
Goldman Sachs
27
Goldman Sachs
New York
$2.37M +$1.09M +399,992 +120%
Northern Trust
28
Northern Trust
Illinois
$2.36M +$672K +247,245 +51%
Qube Research & Technologies (QRT)
29
Qube Research & Technologies (QRT)
United Kingdom
$2.34M +$1.97M +725,894 New
SCM
30
Sio Capital Management
New York
$2.05M – – –
Charles Schwab
31
Charles Schwab
California
$1.85M +$510K +187,505 +49%
Federated Hermes
32
Federated Hermes
Pennsylvania
$1.68M +$1.25M +461,469 +769%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.28M +$1.07M +395,100 New
Acadian Asset Management
34
Acadian Asset Management
Massachusetts
$1.14M +$963K +354,112 New
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$1.06M +$790K +290,584 +759%
Walleye Capital
36
Walleye Capital
New York
$1.05M +$880K +323,600 New
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$1.03M +$871K +320,300 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.03M +$218K +80,148 +34%
AQR Capital Management
39
AQR Capital Management
Connecticut
$934K +$786K +289,088 New
Parallax Volatility Advisers
40
Parallax Volatility Advisers
California
$889K -$19.5K -7,170 -3%
ACM
41
ADAR1 Capital Management
Texas
$888K +$748K +275,000 New
MA
42
MYDA Advisors
New York
$711K +$598K +220,000 New
N
43
Nuveen
North Carolina
$691K -$14.5K -5,342 -2%
Los Angeles Capital Management
44
Los Angeles Capital Management
California
$628K +$529K +194,461 New
LPL Financial
45
LPL Financial
California
$613K +$289K +106,130 +127%
PI
46
Pennant Investors
New Jersey
$552K +$465K +170,900 New
WMSA
47
Weiss Multi-Strategy Advisers
New York
$549K +$261K +96,037 +130%
JGC
48
J. Goldman & Co
New York
$542K +$456K +167,733 New
Jane Street
49
Jane Street
New York
$519K +$102K +37,576 +31%
Squarepoint
50
Squarepoint
New York
$483K +$246K +90,565 +154%
1
2
3 4 5

ARQT Hedge Fund Activity: Q4 2023 in Review

133 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2023, worth a combined $347M — down 2.8% from $357M a quarter earlier.

Fund positioning in ARQT was balanced in Q4 2023: 40 funds opened new positions, 40 closed out, 50 added to existing stakes and 25 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $32.5M. The largest seller was Fidelity Investments, cutting an estimated $19.1M.

  • 133 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2023, down from 134 in Q3 2023.
  • Funds reported $347M of Arcutis Biotherapeutics stock for Q4 2023, down 2.8% quarter-over-quarter.
  • 40 funds opened new Arcutis Biotherapeutics positions in Q4 2023 and 40 closed out, a net change of 0 holders.
  • The largest Arcutis Biotherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $32.5M added.
  • The largest Arcutis Biotherapeutics seller in Q4 2023 was Fidelity Investments, an estimated $19.1M sold.

Based on aggregated 13F filings for Q4 2023.